CDK Inhibitor Combination Using ROS Targeting in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including CDK inhibitors, face challenges such as drug resistance and toxicity, and cancer cells rely on high antioxidant enzyme levels for survival, necessitating a more effective chemotherapeutic regimen.
Innovation Solution
Combining CDK inhibitors with antioxidant enzyme inhibitors, such as thioredoxin reductase and glutathione system inhibitors, to regulate ROS levels and promote apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK inhibitors are used for cancer treatment, then therapeutic efficacy is improved, but drug resistance and toxicity increase
Solution Approach 1:
The patent combines CDK inhibitors with antioxidant enzyme inhibitors (such as thioredoxin reductase inhibitors or glutathione system inhibitors) to create a synergistic combination therapy. This merging of two mechanisms of action addresses the contradiction by enhancing the anti-cancer effect (improving therapeutic efficacy) while the specific targeting of antioxidant enzymes helps overcome drug resistance mechanisms, and the combination allows for reduced individual drug doses that minimize toxicity.
Solution Approach 2:
The patent changes the therapeutic approach by targeting antioxidant enzyme levels as a new parameter in cancer cell survival. By inhibiting antioxidant enzymes (modifying the redox state parameter of cancer cells), the therapy creates oxidative stress that sensitizes cancer cells to CDK inhibition, thereby improving efficacy while allowing lower doses of CDK inhibitors to reduce toxicity.
2Reliability
If antioxidant enzyme levels are increased in cancer cells, then cell survival is improved, but cancer progression is accelerated
Solution Approach 1:
The patent exploits the harmful role of antioxidant enzymes in cancer cell survival by developing inhibitors that convert this protective mechanism into a vulnerability. By inhibiting antioxidant enzymes (such as thioredoxin reductase or glutathione peroxidase), the therapy transforms the cancer cell's reliance on these enzymes for survival into a weakness, causing oxidative stress that kills the cancer cells. This converts the previously beneficial antioxidant system into a harmful target for therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination achieves synergistic effects, enhancing therapeutic efficacy, reducing drug resistance, and minimizing side effects by targeting cancer cells' oxidative stress and survival mechanisms.
Implementation Method 1
The combination achieves synergistic effects, enhancing therapeutic efficacy, reducing drug resistance, and minimizing side effects by targeting cancer cells' oxidative stress and survival mechanisms.
Implementation Method 2
Combining CDK inhibitors with antioxidant enzyme inhibitors, such as thioredoxin reductase and glutathione system inhibitors, to regulate ROS levels and promote apoptosis in cancer cells.
Data Source
AI summary
The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.